Melatonin reduces oxidative stress in the erythrocytes of multiple sclerosis patients with secondary progressive clinical course

被引:65
|
作者
Miller, Elzbieta [1 ,2 ]
Walczak, Anna [3 ]
Majsterek, Ireneusz [3 ]
Kedziora, Jozef [4 ]
机构
[1] Med Univ Lodz, Dept Phys Med, PL-94124 Lodz, Poland
[2] III Gen Hosp Lodz, Neurorehabil Ward, Lodz, Poland
[3] Med Univ Lodz, Dept Chem & Clin Biochem, PL-94124 Lodz, Poland
[4] Nicholas Copernicus Univ, Chair & Dept Biochem, Coll Med Bydgoszcz, Torun, Poland
关键词
Melatonin; Oxidative stress; Multiple sclerosis; DISABILITY STATUS; AUTOXIDATION; STROKE; BRAIN; MICE;
D O I
10.1016/j.jneuroim.2013.02.012
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Oxidative stress plays a major role in multiple sclerosis (MS). melatonin is a potent neuroprotectant. The aims of this study were to determine the actions of melatonin in the reduction of oxidative stress in MS. Therefore, we estimated lipid peroxidation and activities of main antioxidative enzymes in the red blood cells (RBCs) from selective group of MS patients only with secondary progressive (SPMS) clinical form and verified results with functional state. The sixteen (n = 16) SPMS patients were supplemented with melatonin (10 mg daily/30 days). Age matched healthy subjects were used as a control (n = 13). We determined the level of lipid peroxidation by malondialdehyde (MDA) and activities of main antioxidative enzymes: superoxide dismutase (SOD), catalase (CAT) and glutathione peroxide (GPx) in RBCs of SPMS patients. Melatonin caused statistically significant increase of SOD, GPx (p < 0.0001 and p = 0.004065, respectively) and decrease of MDA in erythrocytes of SPMS patients (p = 0.00019). Correlation analysis of Spearman showed positive correlation between SOD and (expanded disability status scale) EDSS scale both before (r = 0.64, p = 0.00756) and after (r = 0.634, p = 0.00834) melatonin treatment. These results demonstrate that supplementation with melatonin SPMS patients should be taken into account, especially in progressive form of MS. (C) 2013 Elsevier B.V. All rights reserved.
引用
收藏
页码:97 / 101
页数:5
相关论文
共 50 条
  • [31] Progressive Onset Multiple Sclerosis: Demographic, Clinical and Laboratory Characteristics of Patients With and Without Relapses in the Course
    Kaymakamzade, Bahar
    Kilic, Ahmet Kasim
    Tuncer Kurne, Asli
    Karabudak, Rana
    NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY, 2019, 56 (01): : 23 - 26
  • [32] Melatonin reduces oxidative stress in surgical neonates
    Gitto, E
    Romeo, C
    Reiter, RJ
    Impellizzeri, P
    Pesce, S
    Basile, M
    Antonuccio, P
    Trimarchi, G
    Gentile, C
    Barberi, I
    Zuccarello, B
    JOURNAL OF PEDIATRIC SURGERY, 2004, 39 (02) : 184 - 188
  • [33] Clinical course of primary progressive multiple sclerosis: fast and slow progression
    Legarda, C.
    Gurevich, M.
    Magalashvili, D.
    Dolev, M.
    Achiron, A.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 95 - 95
  • [34] Epigenetic marks in the brain of patients with secondary progressive multiple sclerosis
    Casaccia, Patrizia
    Mastronardi, Fabrizio
    MULTIPLE SCLEROSIS, 2008, 14 : S60 - S61
  • [35] Chromosomal radiosensitivity in secondary-progressive multiple sclerosis patients
    Petcu, I
    Savu, D
    Vral, A
    Thierens, H
    Nagels, G
    De Ridder, L
    INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, 2004, 80 (09) : 663 - 672
  • [36] The efficacy of copaxone therapy in patients with secondary progressive multiple sclerosis
    Zavalishin, I
    Bejn, B
    Sholomov, I
    Alifirova, V
    Poverennova, I
    Baljazin, V
    Okladnikov, V
    Klushin, D
    Peresedova, A
    Stoida, N
    Zaharova, M
    Adarcheva, L
    Nijazbekova, A
    Askarova, L
    Olejnikov, V
    Rebrova, O
    Durseneva, O
    Kuranova, O
    Orlova, J
    Tel'nova, K
    Goncharova, Z
    Volkova, L
    Turova, E
    Okuneva, I
    Nechaeva, J
    Reikhert, L
    Bychenko, S
    Markina, O
    MULTIPLE SCLEROSIS, 2005, 11 : S84 - S84
  • [37] Safety and Tolerability of Siponimod in Patients with Secondary Progressive Multiple Sclerosis
    Fox, Robert
    Kappos, Ludwig
    Bar-Or, Amit
    Cree, Bruce
    Giovannoni, Gavin
    Gold, Ralf
    Vermersch, Patrick
    Pohlmann, Harold
    Wolf, Christian
    Dahlke, Frank
    Wallstrom, Erik
    Sidorenko, Tatiana
    NEUROLOGY, 2017, 88
  • [38] Evaluation of immunological and clinical parameters in patients with primary progressive and secondary progressive multiple sclerosis: a case control study of 60 patients
    Kitsos, D. K.
    Tsiodras, S.
    Poulios, A.
    Ploubidis, G. B.
    JOURNAL OF NEUROLOGY, 2011, 258 : 200 - 200
  • [39] Siponimod in secondary progressive multiple sclerosis
    Rissardo, Jamir Pitton
    Caprara, Ana Leticia Fornari
    INTERNATIONAL ARCHIVES OF HEALTH SCIENCES, 2020, 7 (03) : 155 - 155
  • [40] Natalizumab in secondary progressive multiple sclerosis
    Edan, Gilles
    LANCET NEUROLOGY, 2018, 17 (05): : 384 - 385